Cite
HARVARD Citation
Alessi, J. et al. (2020). Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Journal for immunotherapy of cancer. 8 (2), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Alessi, J. et al. (2020). Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Journal for immunotherapy of cancer. 8 (2), p. . [Online].